ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 129 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2023. The put-call ratio across all filers is 0.22 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $69,938 | -22.1% | 71,367 | +10.4% | 0.00% | – |
| Q2 2023 | $89,834 | -5.7% | 64,631 | +7.9% | 0.00% | – |
| Q1 2023 | $95,276 | -74.0% | 59,923 | +2.2% | 0.00% | -100.0% |
| Q4 2022 | $365,783 | +678.3% | 58,624 | +759.2% | 0.00% | – |
| Q3 2022 | $47,000 | +95.8% | 6,823 | +90.4% | 0.00% | – |
| Q2 2022 | $24,000 | +50.0% | 3,583 | +1.8% | 0.00% | – |
| Q1 2022 | $16,000 | -11.1% | 3,521 | -1.7% | 0.00% | – |
| Q4 2021 | $18,000 | -57.1% | 3,583 | +3.4% | 0.00% | – |
| Q3 2021 | $42,000 | -42.5% | 3,464 | 0.0% | 0.00% | – |
| Q2 2021 | $73,000 | -26.3% | 3,464 | -2.7% | 0.00% | – |
| Q1 2021 | $99,000 | -2.9% | 3,559 | -9.8% | 0.00% | – |
| Q4 2020 | $102,000 | -74.8% | 3,946 | -56.4% | 0.00% | -100.0% |
| Q3 2020 | $404,000 | -23.2% | 9,052 | -11.6% | 0.00% | -50.0% |
| Q2 2020 | $526,000 | +94.8% | 10,237 | +21.1% | 0.00% | +100.0% |
| Q1 2020 | $270,000 | – | 8,452 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |